Report
Pharvaris 2Q25 update shows all is on track, on-demand phase 3 readout in 4Q25
Pharvaris reported 2Q25 results showing no major surprises and confirming previously communicated timelines, with the next key milestone being topline results from the phase 3 trial of deucrictibant (B2R antagonist, oral tablet) in on-demand HAE in 4Q25 – we are confident in a positive outcome. The company reported a cash position of $ 200m (YE24: $281m), which was supplemented by $ 201m in a public offering in July 2025, providing Pharvaris with a cash runway into 1H27. We continue to see Pharvaris as uniquely positioned in the HAE space, and reiterate our $ 29 TP and Buy rating.
Underlying
Pharvaris NV
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.